This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $29.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
The data that support the findings of this study are available in the mansucripts cited in the Reference section.
Pozdnyakov A, Kulanthaivelu R, Bauman G, Ortega C, Veit-Haibach P, Metser U. The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2022. https://doi.org/10.1038/s41391-022-00544-3.
Baas DJH, Schilham M, Hermsen R, et al. Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection. Prostate Cancer Prostatic Dis. 2022;25:65–70. https://doi.org/10.1038/s41391-021-00452-y.
Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815–22. https://doi.org/10.1016/S0140-6736(16)32401-1.
Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378:1767–77. https://doi.org/10.1056/NEJMoa1801993.
Bertolo R, Vittori M, Cipriani C, et al. Diagnostic pathway of the biopsy-naïve patient suspected for prostate cancer: real-life scenario when multiparametric Magnetic Resonance Imaging is not centralized. Prog En Urol J Assoc Francaise Urol Soc Francaise Urol. 2021;31:739–46. https://doi.org/10.1016/j.purol.2020.12.008.
Panebianco V, Barchetti G, Simone G, et al. Negative multiparametric magnetic resonance imaging for prostate cancer: what’s next? Eur Urol. 2018;74:48–54. https://doi.org/10.1016/j.eururo.2018.03.007.
Clinton TN, Bagrodia A, Lotan Y, Margulis V, Raj GV, Woldu SL. Tissue-based biomarkers in prostate cancer. Expert Rev Precis Med Drug Dev. 2017;2:249–60. https://doi.org/10.1080/23808993.2017.1372687.
Raveenthiran S, Yaxley WJ, Franklin T, et al. Findings in 1123 men with preoperative 68ga-prostate-specific membrane antigen positron emission tomography/computerized tomography and multiparametric magnetic resonance imaging compared to totally embedded radical prostatectomy histopathology: implications for the diagnosis and management of prostate cancer. J Urol. 2022;207:573–80. https://doi.org/10.1097/JU.0000000000002293.
Kalapara AA, Nzenza T, Pan HYC, et al. Detection and localisation of primary prostate cancer using 68 gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. BJU Int. 2020;126:83–90. https://doi.org/10.1111/bju.14858.
Emmett L, Buteau J, Papa N, et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography-computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. Eur Urol. 2021;80:682–9. https://doi.org/10.1016/j.eururo.2021.08.002.
Ferraro DA, Becker AS, Kranzbühler B, et al. Diagnostic performance of 68Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single- center study. Eur J Nucl Med Mol Imaging. 2021;48:3315–24. https://doi.org/10.1007/s00259-021-05261-y.
Koseoglu E, Kordan Y, Kilic M, et al. Diagnostic ability of Ga-68 PSMA PET to detect dominant and non-dominant tumors, upgrading and adverse pathology in patients with PIRADS 4-5 index lesions undergoing radical prostatectomy. Prostate Cancer Prostatic Dis. 2021;24:202–9. https://doi.org/10.1038/s41391-020-00270-8.
Donato P, Roberts MJ, Morton A, et al. Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions “invisible” on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology. Eur J Nucl Med Mol Imaging. 2019;46:20–30. https://doi.org/10.1007/s00259-018-4160-7.
von Klot CAJ, Merseburger AS, Böker A, et al. 68Ga-PSMA PET/CT imaging predicting intraprostatic tumor extent, extracapsular extension and seminal vesicle invasion prior to radical prostatectomy in patients with prostate cancer. Nucl Med Mol Imaging. 2017;51:314–22. https://doi.org/10.1007/s13139-017-0476-7.
Pinaquy JB, De Clermont-Galleran H, Pasticier G, et al. Comparative effectiveness of [(18) F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer. Prostate. 2015;75:323–31. https://doi.org/10.1002/pros.22921.
Mottaghy FM, Heinzel A, Verburg FA. Molecular imaging using PSMA PET/CT versus multiparametric MRI for initial staging of prostate cancer: comparing apples with oranges? Eur J Nucl Med Mol Imaging. 2016;43:1397–9. https://doi.org/10.1007/s00259-016-3389-2.
Vlachostergios PJ, Niaz MJ, Thomas C, et al. Pilot study of the diagnostic utility of 89 Zr-df-IAB2M and 68 Ga-PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer. Prostate 2022;82:483–92. https://doi.org/10.1002/pros.24294.Epub. 2022 Jan 5.
Roberts MJ, Morton A, Donato P, et al. 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:477–82. https://doi.org/10.1007/s00259-020-04944-2.
Roberts MJ, Morton A, Papa N, et al. Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05756-2.
Toriihara A, Nobashi T, Baratto L, et al. Comparison of 3 interpretation criteria for 68Ga- PSMA11 PET based on inter- and intrareader agreement. J Nucl Med. 2020;61:533–9. https://doi.org/10.2967/jnumed.119.232504.
Emmett LM, Papa N, Buteau J, et al. The PRIMARY Score: using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis. J Nucl Med Off Publ Soc Nucl Med. 2022. https://doi.org/10.2967/jnumed.121.263448.
de Feria Cardet RE, Hofman MS, Segard T, et al. Is prostate-specific membrane antigen positron emission tomography/computed tomography imaging cost-effective in prostate cancer: an analysis informed by the proPSMA trial. Eur Urol. 2021;79:413–8. https://doi.org/10.1016/j.eururo.2020.11.043.
Devos G, Vansevenant B, De Meerleer G, et al. Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review. World J Urol. 2021;39:3177–85. https://doi.org/10.1007/s00345-021-03611-x.
Tosco L, Laenen A, Gevaert T, et al. Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial. BMC Cancer. 2018;18:354 https://doi.org/10.1186/s12885-018-4275-z.
Lenis AT, Pooli A, Lec PM, et al. Prostate-specific membrane antigen positron emission tomography/computed tomography compared with conventional imaging for initial staging of treatment-naïve intermediate- and high-risk prostate cancer: a retrospective single-center study. Eur Urol Oncol. 2020;18:S2588–9311. https://doi.org/10.1016/j.euo.2020.08.012. 30139-5
Thalgott M, Düwel C, Rauscher I, et al. One-stop-shop whole-body 68Ga-PSMA-11 PET/MRI compared with clinical nomograms for preoperative T and N staging of high-risk prostate cancer. J Nucl Med. 2018;59:1850–6. https://doi.org/10.2967/jnumed.117.207696.
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Albisinni, S., Sarkis, J., Diamand, R. et al. Prebiopsy 68Ga-PSMA PET imaging: can we improve the current diagnostic pathway for prostate cancer?. Prostate Cancer Prostatic Dis (2022). https://doi.org/10.1038/s41391-022-00593-8